Literature DB >> 3403529

The bacteriophage T4 insertion/substitution vector system. A method for introducing site-specific mutations into the virus chromosome.

H E Selick1, K N Kreuzer, B M Alberts.   

Abstract

A bacteriophage T4 insertion/substitution vector system has been developed as a means of introducing in vitro generated mutations into the T4 chromosome. The insertion/substitution vector is a 2638-base pair plasmid containing the pBR322 origin of replication and ampicillin resistance determinant, a T4 gene 23 promoter/synthetic supF tRNA gene fusion, and a polylinker with eight unique restriction enzyme recognition sites. A T4 chromosomal "target" DNA sequence is cloned into this vector and mutated by standard recombinant DNA techniques. Escherichia coli cells containing this plasmid are then infected with T4 bacteriophage that carry amber mutations in two essential genes. The plasmid integrates into the T4 chromosome by recombination between the plasmid-borne T4 target sequence and its homologous chromosomal counterpart. The resulting phage, termed "integrants," are selectable by the supF-mediated suppression of their two amber mutations. Thus, although the integrants comprise 1-3% or less of the total phage progeny, growth on a nonsuppressing host permits their direct selection. The pure integrant phage can be either analyzed directly for a possible mutant phenotype or transferred to nonselective growth conditions. In the latter case, plasmid-free phage segregants rapidly accumulate due to homologous recombination between the duplicated target sequences surrounding the supF sequence in each integrant chromosome. A major fraction of these segregants will retain the in vitro generated mutation within their otherwise unchanged chromosomes and are isolated as stable mutant bacteriophage. The insertion/substitution vector system thereby allows any in vitro mutated gene to be readily substituted for its wild-type counterpart in the bacteriophage T4 genome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403529

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Double-strand break repair in tandem repeats during bacteriophage T4 infection.

Authors:  D J Tomso; K N Kreuzer
Journal:  Genetics       Date:  2000-08       Impact factor: 4.562

3.  Multiple mechanisms for degradation of bacteriophage T4 soc mRNA.

Authors:  Toshie Kai; Tetsuro Yonesaki
Journal:  Genetics       Date:  2002-01       Impact factor: 4.562

4.  Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes.

Authors:  George Hong; Kenneth N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

5.  Coordination of DNA ends during double-strand-break repair in bacteriophage T4.

Authors:  Bradley A Stohr; Kenneth N Kreuzer
Journal:  Genetics       Date:  2002-11       Impact factor: 4.562

6.  Isolation and genetic characterization of new uvsW alleles of bacteriophage T4.

Authors:  L K Derr; J W Drake
Journal:  Mol Gen Genet       Date:  1990-07

7.  RNA cleavage linked with ribosomal action.

Authors:  Haruyo Yamanishi; Tetsuro Yonesaki
Journal:  Genetics       Date:  2005-07-14       Impact factor: 4.562

8.  Fork regression is an active helicase-driven pathway in bacteriophage T4.

Authors:  David T Long; Kenneth N Kreuzer
Journal:  EMBO Rep       Date:  2009-03-06       Impact factor: 8.807

9.  Recombination-dependent DNA replication stimulated by double-strand breaks in bacteriophage T4.

Authors:  K N Kreuzer; M Saunders; L J Weislo; H W Kreuzer
Journal:  J Bacteriol       Date:  1995-12       Impact factor: 3.490

10.  Regression supports two mechanisms of fork processing in phage T4.

Authors:  David T Long; Kenneth N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.